Ionis Pharmaceuticals Inc
IONS80.300USD
-1.240-1.52%
收盘 01/09, 16:00（美东）报价延迟15分钟
12.94B总市值
亏损市盈率 TTM
关于 Ionis Pharmaceuticals Inc 公司
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Ionis Pharmaceuticals Inc简介
公司代码IONS
公司名称Ionis Pharmaceuticals Inc
上市日期May 17, 1991
CEOMonia (Brett P)
员工数量1069
证券类型Ordinary Share
年结日May 17
公司地址2855 Gazelle Court
城市CARLSBAD
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编92010
电话17609319200
网址https://www.ionis.com/
公司代码IONS
上市日期May 17, 1991
CEOMonia (Brett P)
Ionis Pharmaceuticals Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
179.57K
-437.00%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+4079.00%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
--
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
59.66K
--
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
53.89K
-3241.00%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
48.83K
-8000.00%
Mr. Eugene Schneider, M.D.
Mr. Eugene Schneider, M.D.
Executive Vice President, Chief Clinical Development and Operations Officer
Executive Vice President, Chief Clinical Development and Operations Officer
47.47K
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
36.33K
--
Dr. Eric E. Swayze, Ph.D.
Dr. Eric E. Swayze, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
30.57K
--
Ms. Shannon L. Devers
Ms. Shannon L. Devers
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.49K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Brett P. Monia, Ph.D.
Dr. Brett P. Monia, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
179.57K
-437.00%
Dr. Spencer R. Berthelsen, M.D.
Dr. Spencer R. Berthelsen, M.D.
Independent Director
Independent Director
156.08K
+4079.00%
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
110.50K
--
Dr. Richard S. Geary, Ph.D.
Dr. Richard S. Geary, Ph.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
59.66K
--
Mr. Patrick R. O'Neil, Esq.
Mr. Patrick R. O'Neil, Esq.
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
53.89K
-3241.00%
Mr. Brian Birchler
Mr. Brian Birchler
Executive Vice President, Chief Business Officer
Executive Vice President, Chief Business Officer
48.83K
-8000.00%
收入明细
单位: USD更新时间: 3月4日 周二
单位: USD更新时间: 3月4日 周二
FY2020
FY2019
业务USD
名称
营收
占比
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
由于公司未披露，未能获取相关数据
业务
地区
业务USD
名称
营收
占比
R&D revenue under collaborative agreements
364.56M
49.99%
SPINRAZA royalties
286.58M
39.30%
Product sales, net
70.00M
9.60%
Licensing and other Royalty revenue
8.12M
1.11%
股东统计
更新时间: 11月19日 周三
更新时间: 11月19日 周三
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
14.63%
Capital World Investors
11.09%
The Vanguard Group, Inc.
10.15%
T. Rowe Price Investment Management, Inc.
8.12%
BlackRock Institutional Trust Company, N.A.
5.22%
其他
50.79%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
14.63%
Capital World Investors
11.09%
The Vanguard Group, Inc.
10.15%
T. Rowe Price Investment Management, Inc.
8.12%
BlackRock Institutional Trust Company, N.A.
5.22%
其他
50.79%
股东类型
持股股东
占比
Investment Advisor
68.58%
Investment Advisor/Hedge Fund
19.53%
Hedge Fund
13.84%
Research Firm
2.62%
Pension Fund
1.04%
Bank and Trust
0.81%
Individual Investor
0.75%
Sovereign Wealth Fund
0.28%
Family Office
0.02%
机构持股
更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
841
178.22M
110.03%
-6.52M
2025Q3
815
172.95M
106.78%
-7.24M
2025Q2
801
185.40M
116.34%
+8.33M
2025Q1
826
174.18M
109.45%
-1.97M
2024Q4
819
166.51M
104.84%
-2.69M
2024Q3
814
162.85M
103.55%
+6.60M
2024Q2
810
149.96M
102.64%
-3.87M
2024Q1
792
148.14M
101.63%
-5.27M
2023Q4
782
147.15M
102.53%
-3.26M
2023Q3
763
145.13M
101.24%
-1.40M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
23.69M
14.63%
+46.05K
+0.19%
Sep 30, 2025
Capital World Investors
17.96M
11.09%
+5.24M
+41.17%
Dec 31, 2025
The Vanguard Group, Inc.
16.44M
10.15%
-235.68K
-1.41%
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
13.16M
8.12%
-2.89M
-18.02%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
8.45M
5.22%
-272.23K
-3.12%
Sep 30, 2025
Wellington Management Company, LLP
6.59M
4.07%
+243.03K
+3.83%
Sep 30, 2025
Bellevue Asset Management AG
6.24M
3.86%
-1.61M
-20.49%
Sep 30, 2025
State Street Investment Management (US)
4.39M
2.71%
-141.75K
-3.13%
Sep 30, 2025
Deep Track Capital LP
3.81M
2.35%
-1.08M
-22.15%
Sep 30, 2025
Two Sigma Investments, LP
3.65M
2.25%
-806.92K
-18.11%
Sep 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Invesco Biotechnology & Genome ETF
5.24%
ARK Genomic Revolution ETF
4.11%
Virtus LifeSci Biotech Products ETF
3.34%
Franklin Genomic Advancements ETF
2.69%
Invesco Dorsey Wright Healthcare Momentum ETF
2.57%
First Trust Health Care Alphadex Fund
2.47%
VanEck Morningstar SMID Moat ETF
2.38%
WisdomTree BioRevolution Fund
2.28%
State Street SPDR S&P Biotech ETF
2.28%
Capital Group US Small and Mid Cap ETF
2.04%
查看更多
Invesco Biotechnology & Genome ETF
占比5.24%
ARK Genomic Revolution ETF
占比4.11%
Virtus LifeSci Biotech Products ETF
占比3.34%
Franklin Genomic Advancements ETF
占比2.69%
Invesco Dorsey Wright Healthcare Momentum ETF
占比2.57%
First Trust Health Care Alphadex Fund
占比2.47%
VanEck Morningstar SMID Moat ETF
占比2.38%
WisdomTree BioRevolution Fund
占比2.28%
State Street SPDR S&P Biotech ETF
占比2.28%
Capital Group US Small and Mid Cap ETF
占比2.04%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Ionis Pharmaceuticals Inc的前五大股东是谁？
Ionis Pharmaceuticals Inc 的前五大股东如下：
Fidelity Management & Research Company LLC持有股份：23.69M，占总股份比例：14.63%。
Capital World Investors持有股份：17.96M，占总股份比例：11.09%。
The Vanguard Group, Inc.持有股份：16.44M，占总股份比例：10.15%。
T. Rowe Price Investment Management, Inc.持有股份：13.16M，占总股份比例：8.12%。
BlackRock Institutional Trust Company, N.A.持有股份：8.45M，占总股份比例：5.22%。
Fidelity Management & Research Company LLC持有股份：23.69M，占总股份比例：14.63%。
Capital World Investors持有股份：17.96M，占总股份比例：11.09%。
The Vanguard Group, Inc.持有股份：16.44M，占总股份比例：10.15%。
T. Rowe Price Investment Management, Inc.持有股份：13.16M，占总股份比例：8.12%。
BlackRock Institutional Trust Company, N.A.持有股份：8.45M，占总股份比例：5.22%。
Ionis Pharmaceuticals Inc的前三大股东类型是什么？
Ionis Pharmaceuticals Inc 的前三大股东类型分别是：
Fidelity Management & Research Company LLC
Capital World Investors
The Vanguard Group, Inc.
Fidelity Management & Research Company LLC
Capital World Investors
The Vanguard Group, Inc.
有多少机构持有Ionis Pharmaceuticals Inc(IONS)的股份？
截至2025Q4，共有841家机构持有Ionis Pharmaceuticals Inc的股份，合计持有的股份价值约为178.22M，占公司总股份的110.03%。与2025Q3相比，机构持股有所增加，增幅为3.25%。
哪个业务部门对Ionis Pharmaceuticals Inc的收入贡献最大？
在FY2020，R&D revenue under collaborative agreements业务部门对Ionis Pharmaceuticals Inc的收入贡献最大，创收364.56M，占总收入的49.99%。
